Market Cap
$18.7M
LFWD
Lifeward Ltd.
$5.85 ▼ -1.85%
Prev close $5.96Market cap$18.7M
12-mo target$20.00 (+241.9%)
High Impact Filing (7/10) Healthcare & Medical Devices
Snapshot
The big-picture read on LFWD right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Social Sentiment
67° Warm
SEC Reports
14
Press Releases
4
Price chart 30d -17.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 trading_halt
Halt Resumed: LFWD — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-01T13:38:22.000Z | Resumed 2026-10-01T13:43:22.000Z
Aug 20, 2026 Insider
Aug 14, 2026 SEC Gabay Avraham was granted 13,643 shares
Director
Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), its strongest quarter since Q4 2024, driven by growth in ReWalk a
8-K — Impact 6/10
Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), slightly above consensus, but GAAP EPS of -$4.12 missed the -$1.2
PRESS-RELEASE — Impact 6/10
Aug 14, 2026 Insider
Zamir Haggai was granted 6,711 shares
Director
Aug 14, 2026 Insider
Aug 11, 2026 SEC Greenwald Yonason was granted 6,711 shares
Director
Lifeward Ltd.'s S-3 shelf registration (File No. 333-297919) became effective on August 10, 2026. This allows the compan
EFFECT — Impact 7/10
Lifeward Ltd. has closed a strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein
Impact 8/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Mar 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Nov 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Mar 11, 2025 | Lake Street | MAINTAIN | Buy | 45% |
| Mar 11, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Feb 20, 2025 | Lake Street | MAINTAIN | Buy | 45% |
| Feb 20, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Feb 10, 2025 | Laidlaw & Co. | INITIATE | Buy | — |
| Nov 13, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 16, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 16, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 2 covering analysts think LFWD trades over the next 12 months.
$20.00 +241.9% upside Strong Buy
Current$5.85 Low$10.00 Median$20.00 High$30.00 2 analysts
$10.00$30.00
Analyst rating None as of Oct 3, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 0 bullish, 6 bearish, 1 mixed, 7 neutral · avg impact 4.7/10.Plus 4 press releases.
MIXED8-K6/10
Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), its strongest quarter since Q4 2024, driven b
Aug 14, 2026
BEARISHPRESS-RELEASE6/10
Lifeward reported Q2 2026 revenue of $6.6M (+16% YoY), slightly above consensus, but GAAP EPS of -$4
Aug 14, 2026
BEARISHEFFECT7/10
Lifeward Ltd.'s S-3 shelf registration (File No. 333-297919) became effective on August 10, 2026. Th
Aug 11, 2026
NEUTRALPRESS-RELEASE2/10
Lifeward announced it will report Q2 2026 results on August 14, 2026, but no financial data, EPS, re
Aug 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
trading_halt
Halt Resumed: LFWD — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-01T13:38:22.000Z | Resumed 2026-10-01T13:43:22.000Z
Oct 1, 2026
trading_halt
Trading Halt: LFWD — LUDP (Volatility Trading Pause)
Lifeward Ltd Ord | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 15, 2026
other
Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use
Aug 14, 2026
earnings
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum
Aug 14, 2026
earnings_calendar
LFWD Q2 2026 Earnings Scheduled — 2026-08-14
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.04 | $-1.04–$-1.04 | 54.4% | -10.6% | — | $0.0B | 1 |
| Next Q | $-0.79 | $-0.79–$-0.79 | 72.3% | -5.3% | — | $0.0B | 1 |
| Current FY | $-5.02 | $-5.02–$-5.02 | 62.1% | -9.6% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-1.42 | $-1.84–$-0.99 | 81.3% | +21.8% | 1↑ 1↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.040 | — |
| 7d ago | $-0.940 | -0.100 |
| 30d ago | $-0.940 | -0.100 |
| 60d ago | $-0.940 | -0.100 |
| 90d ago | $-0.940 | -0.100 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Gabay Avraham | Director | AWARD | 13,643 | — | — |
| Aug 14, 2026 | Zamir Haggai | Director | AWARD | 6,711 | — | — |
| Aug 14, 2026 | Greenwald Yonason | Director | AWARD | 6,711 | — | — |
| May 1, 2026 | Rose Keith Dale | Chief Medical Officer | AWARD | 15,000 | — | — |
| Mar 25, 2026 | Kidron Miriam | Director | AWARD | 7,657 | — | — |
| Mar 25, 2026 | KIDRON NADAV | Director | AWARD | 7,657 | — | — |
| Mar 25, 2026 | Reznick Yehuda | Director | AWARD | 7,657 | — | — |
| Mar 25, 2026 | Grant William Mark | President & CEO | AWARD | 172,698 | — | — |
| Mar 25, 2026 | Adar Almog | Chief Financial Officer | AWARD | 39,934 | — | — |
| Mar 25, 2026 | Rozenbaum Moshe H | Director | AWARD | 11,485 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LFWD.
Shares short
104,836
Settlement Sep 15, 2026
Change vs prior
-6.5%
Semi-monthly cycle
Days to cover
22.7
At avg daily volume
Of shares outstanding
≈3.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Oct 1, 2026 | LUDP | Volatility Pause | Resumed |
All LFWD filing & press-release reports (18)
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- EFFECT reportAug 11, 2026
- PRESS-RELEASE reportAug 7, 2026
- 8-K reportMay 19, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 15, 2026
- EFFECT reportMay 13, 2026
- PRESS-RELEASE reportMay 11, 2026
- S-3 reportApr 27, 2026
- 3 reportMar 27, 2026
- 3 reportMar 27, 2026
- PRESS-RELEASE reportMar 25, 2026
- 8-K reportMar 18, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 13, 2026
- PRESS-RELEASE reportMar 10, 2026
- 8-K reportFeb 25, 2026